Evotec and Novo Nordisk launched LAB eN² in September 2023 to nurture early research from academic institutions into novel therapeutics.

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing ...

Novo Nordisk and Evotec have selected three projects from Boston University, Harvard University in collaboration with Mass General ...

The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of ...

Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects ...

Novo Holdings, the parent company of Novo Nordisk (NYSE:NVO), and Mubadala Investment are among Evotec’s other significant shareholders. "The combination of Halozyme and Evotec would diversify ...

Evotec's other major shareholders are Novo Nordisk (NOVOb.CO), opens new tab parent Novo Holdings and Mubadala Investment. "The combination of Halozyme and Evotec would diversify and extend ...

Novo Nordisk continues to witness strong growth across its portfolio of diabetes and obesity care medications. The company's tailwinds include expanded indications and new geographic markets.

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

(IN BRIEF) Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects focused on addressing cardiometabolic diseases ...

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing ...